Pasireotide Pamoate

ๅŒ็พŸ่˜้…ธๅธ•็‘ž่‚ฝ

Report date: 2026/03/12 20:00:16

Base Information

Drug NamePasireotide Pamoate
Drug Alias Nameๅธ•็‘ž่‚ฝๅŒ็พŸ่˜้…ธ็›ๅŒ็พŸ่˜้…ธๅธ•็‘ž่‚ฝๅพฎ็ƒSignifor lar
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSomatostatin receptor 5 agonistsSomatostatin receptor 3 agonistsSomatostatin receptor 2 agonists +[4]ย 
TargetsSomatostatin receptor 3Somatostatin receptor 1Somatostatin receptor 5 +[4]ย 
Therapy Area/IndicationsCushing SyndromePituitary ACTH HypersecretionAcromegaly +[7]ย 
Global Approved IndicationsAcromegalyGigantism
Approved Indications in ChinaAcromegaly
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/15
Country/TerritoryCzechiaBelgiumCanada +[30]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCushing SyndromePituitary ACTH HypersecretionAcromegaly +[6]ย 
Inactive IndicationsMeningioma

Other Information

ATC CodeH01CB05